Cipher CIP-isotretinoin regulatory path
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cipher plans to meet with FDA to determine whether its CIP-isotretinoin acne product should be filed as a 505(b)(2) NDA or as an abbreviated application, the firm says Sept. 6. FDA is questioning the validity of the 505(b)(2) pathway "since they consider [the formulation] eligible for submission as an abbreviated new drug application," Cipher states. The company submitted the NDA, which it maintains should be a 505(b)(2) application, in the second quarter but FDA deemed the filing unacceptable in its current form. Cipher is pointing to food effect advantages with its isotretinoin formulation compared to Roche's Accutane brand and the three other branded generic versions of the retinoid to argue for regulation as a new product, not a generic...
You may also be interested in...
Cipher isotretinoin "approvable"
Cipher's CIP-isotretinoin is "approvable" May 1, with FDA requesting additional clinical data and further chemistry, manufacturing and controls details, the company says May 2. The firm believes "the data is on hand," but cautions that "we cannot rule out the possibility that a further clinical trial will be required." Cipher characterizes the approvable decision as "encouraging." FDA initially had refused to file the application (1Pharmaceutical Approvals Monthly September 2005, In Brief). Cipher claims its formulation of the retinoid has food effect advantages over Roche's Accutane and generic isotretinoins...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.